{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:10:24Z","timestamp":1790151024489,"version":"4.0.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015086","name":"AOP Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ropeginterferon alfa-2b (ropegIFN-\u03b12b or ropeginterferon) has emerged as a therapeutic option for patients with myeloproliferative neoplasms, particularly polycythemia vera (PV), with potential disease-modifying effects. This systematic review aimed to evaluate the efficacy and safety of ropeginterferon across clinical and real-world studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, and Web of Science was conducted to identify studies reporting clinical outcomes of ropeginterferon in patients with MPNs. An additional PubMed search was performed to capture recently published studies. Eligible studies were screened according to predefined inclusion criteria. Data on hematologic, molecular, clinical, and safety outcomes were extracted and narratively synthesized. A proportional meta-analysis was conducted for selected outcomes, including complete hematologic response (CHR), partial molecular response (PMR), and grade \u22653 cytopenias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 18 studies involving 1,836 patients were included. Pooled analysis demonstrated that CHR rates increased over time, from 26% at 3\u00a0months to 59% at 12\u00a0months, with an overall pooled estimate of 56% (95% CI: 46%\u201366%). PMR was achieved in 37% of patients (95% CI: 20%\u201359%), although with substantial heterogeneity. Molecular responses were supported by consistent reductions in\n                      <jats:italic>JAK2<\/jats:italic>\n                      allele burden across studies. Clinical outcomes showed improvements in spleen size and symptom burden in several cohorts. Ropeginterferon was generally well tolerated. The pooled proportion of grade \u22653 cytopenias was 3% (95% CI: 1%\u201310%), and severe hepatotoxicity was uncommon, typically occurring in \u22645% of patients. Most adverse events were low grade, with infrequent treatment discontinuations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RopegIFN-\u03b12b demonstrates favorable efficacy and safety profiles in patients with MPNs, especially in PV, with evidence of progressive hematologic and molecular responses over time. These findings support its role as a potentially disease-modifying therapy, although further standardized and long-term studies, focusing on ET and MF, are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261337306<\/jats:ext-link>\n                      , identifier CRD420261337306.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1841557","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:46:12Z","timestamp":1790149572000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Aadhila Abbas","family":"Manthiri","sequence":"first","affiliation":[{"name":"College of Pharmacy, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen Haj","family":"Saleh","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marrita","family":"Rabadi","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Dalol","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Mesilhy","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usra","family":"Elshaikh","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Health Sciences, QU Health, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"","journal-title":"Blood Cancer J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evid."},{"key":"B5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","article-title":"Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-Year drug survival and efficacy outcomes","volume":"103","author":"Barbui","year":"2024","journal-title":"Ann. Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1097\/HS9.0000000000000516","article-title":"Challenges and perspectives for therapeutic targeting of myeloproliferative neoplasms","volume":"5","author":"Brkic","year":"2021","journal-title":"HemaSphere"},{"key":"B8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/cncr.10663","article-title":"Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon alpha\u20102b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e70007","DOI":"10.1002\/jha2.70007","article-title":"Real world management of cytopenias and infections in patients with myelofibrosis treated with ruxolitinib","volume":"6","author":"Butler","year":"2025","journal-title":"eJHaem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.clml.2025.06.011","article-title":"Real-World evidence on outcomes and safety of Ropeginterferon Alfa-2b in patients with myeloproliferative neoplasms: a retrospective cohort study","volume":"25","author":"Chang","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e7166","DOI":"10.1002\/cam4.7166","article-title":"Treatment outcome and germline predictive factors of ropeginterferon alpha\u20102b in myeloproliferative neoplasm patients","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/jcm15010128","article-title":"Real-World retrospective report on the efficacy, tolerability, and molecular responses to Ropeginterferon-\u03b12b in patients with myeloproliferative neoplasms","volume":"15","author":"Christen","year":"2025","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e473912","DOI":"10.1200\/EDBK-25-473912","article-title":"Pegylated interferons: still a major player for the treatment of myeloproliferative neoplasms","volume":"45","author":"Daunov","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/14737140.2025.2592736","article-title":"Ropeginterferon alfa-2b in polycythemia vera: redefining disease control through molecular targeting","volume":"26","author":"De Fazio","year":"2026","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/BTT.S4169","article-title":"Long-term pegylated interferon-\u03b1 and its potential in the treatment of melanoma","volume":"3","author":"Dummer","year":"2009","journal-title":"Biol. Targets Ther."},{"key":"B6","volume-title":"Besremi","year":"2018"},{"key":"B16","volume-title":"Novel Drug Approvals for 2021","year":"2025"},{"key":"B52","article-title":"FDA approves treatment for essential Thrombocythemia","year":"2026"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","article-title":"Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment","volume":"37","author":"Gisslinger","year":"2023","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s12185-021-03171-1","article-title":"Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis","volume":"114","author":"Gu","year":"2021","journal-title":"Int. J. Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","article-title":"Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms","volume":"120","author":"Huang","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12185-026-04163-9","article-title":"Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study","volume":"123","author":"Inano","year":"2026","journal-title":"Int. J. Hematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-024-03846-5","article-title":"Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera","volume":"120","author":"Kirito","year":"2024","journal-title":"Int. J. Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"108110","DOI":"10.1016\/j.leukres.2025.108110","article-title":"Low-dose ropeginterferon alfa-2b and peginterferon alfa-2a have comparable efficacy and tolerability in polycythemia vera","volume":"158","author":"Lee","year":"2025","journal-title":"Leuk. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: european LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12885-024-13383-3","article-title":"Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial","volume":"25","author":"McIlroy","year":"2025","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1016\/S2352-3026(25)00264-9","article-title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","volume":"12","author":"Mesa","year":"2025","journal-title":"Lancet Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1007\/s00277-025-06701-7","article-title":"Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis","volume":"104","author":"Nada","year":"2025","journal-title":"Ann. Hematol."},{"key":"B33","volume-title":"Study Quality Assessment Tools","year":"2021"},{"key":"B34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00277-024-05809-6","article-title":"Real-life use of ropeg-interferon \u03b12b in polycythemia vera: patient selection and clinical outcomes","volume":"103","author":"Palandri","year":"2024","journal-title":"Ann. Hematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2478\/prilozi-2023-0047","article-title":"Effectiveness of ropeginterferon Alfa-2B in high-risk patients with Philadelphia chromosome negative myeloproliferative Neoplasms\u2013 evaluation of clinicohaematologic response, and safety profile: Single centre experience","volume":"44","author":"Popova-Labachevska","year":"2023","journal-title":"PRILOZI"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","article-title":"Exposure\u2013efficacy and exposure\u2013safety analyses of ropeginterferon alfa\u20102b treatment in patients with polycythaemia vera","volume":"90","author":"Qin","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1055\/s-2006-942761","article-title":"Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders","volume":"32","author":"Quint\u00e1s-Cardama","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"B40","volume-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00277-025-06480-1","article-title":"A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA adverse event reporting system (FAERS) database","volume":"104","author":"Reeves","year":"2025","journal-title":"Ann. Hematol."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis with R","author":"Schwarzer","year":"2015"},{"key":"B43","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/curroncol32060339","article-title":"Myelofibrosis: treatment options after ruxolitinib failure","volume":"32","author":"Stuckey","year":"2025","journal-title":"Curr. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","article-title":"Effective management of polycythemia vera with ropeginterferon Alfa-2b treatment","volume":"13","author":"Suo","year":"2024","journal-title":"J. Hematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","first-page":"20406207241229588","DOI":"10.1177\/20406207241229588","article-title":"Interferons in the treatment of myeloproliferative neoplasms","volume":"15","author":"Vachhani","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"B50","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in meta-analyses","author":"Wells","year":"2000"},{"key":"B51","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ijc.35411","article-title":"Hematologic and molecular responses to ropeginterferon alfa\u20102b therapy of polycythemia vera: 48\u2010week results from a prospective study","volume":"157","author":"Yoon","year":"2025","journal-title":"Int. J. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1841557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:46:14Z","timestamp":1790149574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1841557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":52,"alternative-id":["10.3389\/fphar.2026.1841557"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1841557","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1841557"}}